PTGX (Protagonist Therapeutics) Other Operating Expense : $0.0 Mil (TTM As of Jun. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Protagonist Therapeutics Other Operating Expense?

Protagonist Therapeutics's Other Operating Expense for the three months ended in Jun. 2024 was $-0.0 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Jun. 2024 was $0.0 Mil.

Protagonist Therapeutics's quarterly Other Operating Expense increased from Dec. 2023 ($0.0 Mil) to Mar. 2024 ($0.0 Mil) but then declined from Mar. 2024 ($0.0 Mil) to Jun. 2024 ($-0.0 Mil).

Protagonist Therapeutics's annual Other Operating Expense declined from Dec. 2021 ($-0.0 Mil) to Dec. 2022 ($-0.0 Mil) but then increased from Dec. 2022 ($-0.0 Mil) to Dec. 2023 ($-0.0 Mil).

Protagonist Therapeutics Other Operating Expense Historical Data

The historical data trend for Protagonist Therapeutics's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Protagonist Therapeutics Other Operating Expense Chart

Protagonist Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Operating Expense

Get a 7-Day Free Trial

Protagonist Therapeutics Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Other Operating Expense	Get a 7-Day Free Trial															-	-	-	-	-

Protagonist Therapeutics Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.0 Mil.

Protagonist Therapeutics Other Operating Expense Related Terms

Thank you for viewing the detailed overview of Protagonist Therapeutics's Other Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Protagonist Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Protagonist Therapeutics Inc (NAS:PTGX) » Definitions » Other Operating Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

7707 Gateway Boulevard, Suite 140, Newark, CA, USA, 94560

Website

https://www.protagonist-inc.com

Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.

Executives

Asif Ali	officer: Chief Financial Officer	7707 GATEWAY BLVD., SUITE 140, NEWARK CA 94560
William D. Waddill	director	C/O CALITHERA BIOSCIENCES, 343 OYSTER POINT BLVD, SUITE 200, SO. SAN FRANCISCO CA 94080
Patel Dinesh V Ph D	director, officer: President and CEO	C/O PROTAGONIST THERAPEUTICS, INC., 521 COTTONWOOD DRIVE, SUITE 100, MILPITAS CA 95035
Suneel Gupta	officer: Chief Development Officer	7707 GATEWAY BLVD., SUITE 140, NEWARK CA 94560
Arturo Md Molina	officer: Chief Medical Officer	10990 WILSHIRE BLVD, SUITE 1200, LOS ANGELES CA 90024
Swisher Daniel N Jr	director	C/O SUNESIS PHARMACEUTICALS, INC., 395 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080
Lewis T Williams	director	C/O FIVE PRIME THERAPEUTICS, INC., TWO CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080
Sarah B. Noonberg	director	331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Sarah A O'dowd	director	3185 LAURELVIEW COURT, FREMONT CA 94538
Harold E Selick	director
Bryan Giraudo	director	7707 GATEWAY BOULEVARD, SUITE 140, NEWARK CA 94560
Donald A. Kalkofen	officer: Chief Financial Officer	7707 GATEWAY BOULEVARD, SUITE 140, NEWARK CA 94560
David Y Liu	officer: Chief Scientific Officer	C/O PROTAGONIST THERAPEUTICS, INC., 521 COTTONWOOD DRIVE, SUITE 100, MILPITAS CA 95035
Chaitan Phd Khosla	director	3832 BAY CENTER PLACE, HAYWARD CA 94545
Richard S Shame	officer: Chief Medical Officer	C/O PROTAGONIST THERAPEUTICS, INC., 521 COTTONWOOD DRIVE, SUITE 100, MILPITAS CA 95035